This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Clinical Study to Assess Safety and Efficacy of a Tumor Vaccine in Patients With Advanced Renal Cell Carcinoma (ASET) (ASET)

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Mologen AG Identifier:
First received: December 22, 2010
Last updated: March 22, 2017
Last verified: March 2016
This is a Phase 1/2, proof-of-principle clinical study to assess safety and efficacy of a intradermally administered tumor vaccine (MGN1601). The study will be conducted in patients with advanced renal cell carcinoma.

Condition Intervention Phase
Stage IV Renal Cell Cancer Biological: MGN1601 Phase 1 Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1/2, Proof-of-Principle, Multi-Center, Open-Label, Single-Arm, Non-randomized Clinical Study to Assess Safety and Efficacy of a Tumor Vaccine Consisting of Genetically Modified Allogeneic (Human) Tumor Cells for the Expression of IL-7, GM-CSF, CD80 and CD154, in Fixed Combination With a DNA-based Double Stem Loop Immunomodulator in Patients With Advanced Renal Cell Carcinoma (ASET Study)

Resource links provided by NLM:

Further study details as provided by Mologen AG:

Primary Outcome Measures:
  • Assessment of safety profile of MGN1601 [ Time Frame: Treatment phase (12 weeks), extension phase (120 weeks, if applicable), plus 5 years follow-up ]

Secondary Outcome Measures:
  • Assessment of potential autoimmune effects of MGN1601 [ Time Frame: Treatment phase (12 weeks), extension phase (120 weeks, if applicable) plus 5 years follow-up (if applicable) ]
  • Assessment of the presence of MIDGE vectors [ Time Frame: Treatment phase (12 weeks) ]
  • Assessment of the immune response to MGN1601 [ Time Frame: Treatment phase (12 weeks), extension phase (120 weeks, if applicable) ]
  • Evaluation of clinical and radiological response to MGN1601 [ Time Frame: Treatment phase (12 weeks), extension phase (120 weeks, if applicable) plus 5 years follow-up ]

Estimated Enrollment: 24
Study Start Date: December 2010
Estimated Study Completion Date: August 2018
Primary Completion Date: August 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Study medication Biological: MGN1601
Genetically modified allogeneic (human) tumor cells for the expression of IL-7, GM-CSF, CD80 and CD154, in fixed combination with a DNA-based double stem loop immunomodulator (dSLIM)

Detailed Description:

Twenty four patients with advanced RCC will be included in this open, single-arm study.

The treatment will last 12 weeks. The investigational product (MGN1601) will be administered intradermally for a total of 8 applications, whereas the first 3 applications will be administered weekly, and the following 5 applications will be administered bi-weekly.

Patients who will develop disease control (CR, PR, or SD) by week 12 will be proposed to participate in the extension phase of the study. The extension phase will be continued until disease progression in each patient, however, maximally up to week 120 (total treatment duration 2.5 years). During this time period the investigational product will be administered 5 times by weeks 24, 36, 48, 72, and 120.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male and female subjects older than 18 years of age
  • Histologically confirmed renal cell carcinoma
  • Radiologically confirmed advanced disease defined as unresectable locally reccurrent or metastatic disease (AJCC Stage IV)
  • Previous nephrectomy
  • No standard therapy is available for the patient
  • At least 4 weeks after previous radiotherapy prior to study treatment
  • At least 1 week after previous systemic therapy prior to study treatment
  • At least one lesion measurable by modified RECIST criteria
  • ECOG performance status 0-1
  • Adequate organ function including hematopoietic organs
  • MSKCC prognostic ctiteria < 3 predictors of short survival
  • Negative urine pregnancy test in women with childbearing potential
  • Women of childbearing potential and all male participants are willing to use acceptable methods of contraception (birth control pills, barriers)
  • Expected adequacy of follow-up
  • Signed informed consent form (ICF).

Exclusion Criteria:

  • Clinically significant concomitant diseases or conditions unrelated to the underlying malignancy or therapy, which in opinion of the investigator would lead to an unacceptable risk for the subject to participate in the study
  • Known hypersensitivity to any component of the study drug
  • Prior or current other malignancy, except adequately treated superficial bladder cancer, basal or squamous cell carcinoma of the skin or other cancer for which the subject has been disease free for more than 3 years
  • Active brain metastases except adequately treated brain metastases with no progression for at least 3 months
  • Active or uncontrolled infections
  • Transfusion-dependent anemia
  • History of autoimmune disease or immune deficiency
  • Concurrent chronic systemic immune therapy, corticosteroids or other immunosuppressant medication
  • Concurrent radiotherapy within the last 4 weeks prior to study treatment and/or during the course of the study
  • Concurrent immunotherapy or targeted therapy within the last 1 week prior to study treatment and/or during the course of the study
  • HIV seropositivity or active hepatitis B or C infection
  • Planned major surgery during the study
  • Participation in other clinical studies during this clinical study
  • Vaccination within 3 months prior to the first treatment day
  • Any medical, mental, psychological or psychiatric condition which in opinion of the investigator would not permit the subject to complete the study or understand the patient information
  • Pregnancy and/or nursing
  • Presence of drug and/or alcohol abuse
  • Commitment to an institution by virtue of an order issued either by judicial or administrative authorities.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01265368

Charité - Universtitäsmedizin Berlin, Klinik für Urologie
Berlin, Germany, 10117
Universitätsklinikum Bonn, Med. Klinik und Poliklinik, Hämatologie und Onkologie
Bonn, Germany, 53127
Medizinische Hochschule Hannover, Klinik für Hämatologie, Hämostaseologie, Onkologie und Stammzelltransplantation OE6860
Hannover, Germany, 30625
Sponsors and Collaborators
Mologen AG
Principal Investigator: Viktor Grünwald, Prof. Dr. MHH Hannover
  More Information

Additional Information:
Responsible Party: Mologen AG Identifier: NCT01265368     History of Changes
Other Study ID Numbers: MGN1601-CT1
2009-016853-16 ( EudraCT Number )
Study First Received: December 22, 2010
Last Updated: March 22, 2017

Keywords provided by Mologen AG:
Advanced Renal Cell Carcinoma
Tumor Vaccine
Cell-based Therapy

Additional relevant MeSH terms:
Carcinoma, Renal Cell
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Kidney Neoplasms
Urologic Neoplasms
Urogenital Neoplasms
Neoplasms by Site
Kidney Diseases
Urologic Diseases
Immunologic Factors
Adjuvants, Immunologic
Physiological Effects of Drugs processed this record on August 18, 2017